by Madaline Spencer | Sep 3, 2025
Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses naxitamab combination therapy for the treatment of patients with...
by Madaline Spencer | Sep 2, 2025
The U.S. Food and Drug Administration (FDA) has approved the updated Risk Evaluation and Mitigation Strategy (REMS) for Filspari (sparsentan) for the treatment of IgA nephropathy (IgAN). IgAN is a rare disorder that occurs when IgA accumulates in the kidneys. In the...
by Madaline Spencer | Sep 2, 2025
Robin Williams, MD, Pediatric Hematology Oncologist at M Health Fairview Masonic Children’s Hospital, discusses her experience diagnosing and treating a patient with Castleman disease (CD). CD is a rare condition that affects the lymph nodes and related...
by Madaline Spencer | Sep 1, 2025
Lori Bulpett, Manager of Patient Advocacy at Chiesi Global Rare Diseases, discusses mental health in patients with acromegaly. Acromegaly is a hormonal disorder that results from the overproduction of growth hormone in the pituitary gland. It is most...
by Madaline Spencer | Aug 29, 2025
The U.S. Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare viral disease characterized by benign tumors in the respiratory tract. The tumors...
